Sinovac Biotech (Sinovac Biotech) EPS (Basic) : $-3.62 (TTM As of Jun. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech EPS (Basic)?

Sinovac Biotech's basic earnings per share (Basic EPS) for the six months ended in Jun. 2023 was $0.14. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was $-3.62.

Sinovac Biotech's EPS (Diluted) for the six months ended in Jun. 2023 was $0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-3.62.

Sinovac Biotech's EPS without NRI for the six months ended in Jun. 2023 was $-0.32. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -4.07.

During the past 12 months, Sinovac Biotech's average EPS without NRIGrowth Rate was -112.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 33.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 82.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Sinovac Biotech's highest 3-Year average EPS without NRI Growth Rate was 480.40% per year. The lowest was -138.70% per year. And the median was 17.20% per year.

Sinovac Biotech EPS (Basic) Historical Data

The historical data trend for Sinovac Biotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech EPS (Basic) Chart

Sinovac Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

0.34

0.42

1.06

85.20

1.08

Sinovac Biotech Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EPS (Basic)	Get a 7-Day Free Trial															51.42	33.78	4.84	-3.76	0.14

Sinovac Biotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sinovac Biotech's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(113.866	-	5.982)	/	99.502
	=	1.08

Sinovac Biotech's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(16.918	-	2.958)	/	99.577
	=	0.14

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-3.62

Sinovac Biotech (NAS:SVA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sinovac Biotech EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech (Sinovac Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Executives

Lily Wang	director, 10 percent owner, officer: Chief Financial Officer	300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc	10 percent owner	PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong	director, 10 percent owner, officer: President and CEO
Terry G Bowering	director, 10 percent owner, officer: President, CEO	10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6